Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data.

Franco M, Jeggari A, Peuget S, Böttger F, Selivanova G, Alexeyenko A.

Sci Rep. 2019 Feb 20;9(1):2379. doi: 10.1038/s41598-019-39019-2.

2.

MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts.

Zhang F, Zakaria SM, Högqvist Tabor V, Singh M, Tronnersjö S, Goodwin J, Selivanova G, Bartek J, Castell A, Larsson LG.

Cell Cycle. 2018;17(24):2697-2715. doi: 10.1080/15384101.2018.1553339. Epub 2018 Dec 17.

3.

RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.

Azatyan A, Gallo-Oller G, Diao Y, Selivanova G, Johnsen JI, Zaphiropoulos PG.

Cancer Lett. 2019 Feb 1;442:341-350. doi: 10.1016/j.canlet.2018.11.005. Epub 2018 Nov 14.

4.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2017 Dec 1;292(48):19607. doi: 10.1074/jbc.AAC117.000815. No abstract available.

5.

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis.

Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G.

Cancer Cell. 2017 May 8;31(5):724-726. doi: 10.1016/j.ccell.2017.04.014. No abstract available.

6.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arnér ES, Wiman KG.

Cell Death Dis. 2017 Apr 13;8(4):e2751. doi: 10.1038/cddis.2016.137. No abstract available.

7.

[The prevalence of overweight and obesity in moscow pregnant women and principles of alimentary correction of these conditions].

Shilina NM, Selivanova GA, Braginskaya SG, Gmoshinskaya MV, Kon' IY, Fateeva EM, Safronova AI, Toboleva MA, Larionova ZG, Kurkova VI.

Vopr Pitan. 2016;85(3):61-70. doi: 10.24411/0042-8833-2016-00036. Epub 2016 Jun 23. Russian.

PMID:
30645904
8.

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors.

Dickinson ER, Jurneczko E, Nicholson J, Hupp TR, Zawacka-Pankau J, Selivanova G, Barran PE.

Front Mol Biosci. 2015 Jul 10;2:39. doi: 10.3389/fmolb.2015.00039. eCollection 2015.

9.

The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death.

Xu J, Eriksson SE, Cebula M, Sandalova T, Hedström E, Pader I, Cheng Q, Myers CR, Antholine WE, Nagy P, Hellman U, Selivanova G, Lindqvist Y, Arnér ES.

Cell Death Dis. 2015 Jan 22;6:e1616. doi: 10.1038/cddis.2014.574.

10.

Pharmacological reactivation of p53 as a strategy to treat cancer.

Zawacka-Pankau J, Selivanova G.

J Intern Med. 2015 Feb;277(2):248-259. doi: 10.1111/joim.12336. Review.

11.

Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.

Ireno IC, Wiehe RS, Stahl AI, Hampp S, Aydin S, Troester MA, Selivanova G, Wiesmüller L.

Carcinogenesis. 2014 Oct;35(10):2273-82. doi: 10.1093/carcin/bgu160. Epub 2014 Aug 1.

PMID:
25085902
12.

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.

Li H, Zhang Y, Ströse A, Tedesco D, Gurova K, Selivanova G.

Cell Death Differ. 2014 Sep;21(9):1493-502. doi: 10.1038/cdd.2014.69. Epub 2014 Jun 27.

13.

Wild type p53 reactivation: from lab bench to clinic.

Selivanova G.

FEBS Lett. 2014 Aug 19;588(16):2628-38. doi: 10.1016/j.febslet.2014.03.049. Epub 2014 Apr 12. Review.

14.

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.

Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, Eriksson S, Hedström E, Issaeva N, Kel A, Arnér ES, Selivanova G.

Cell Death Differ. 2014 Apr;21(4):612-23. doi: 10.1038/cdd.2013.186. Epub 2014 Jan 10.

15.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arnér ES, Wiman KG.

Cell Death Dis. 2013 Oct 24;4:e881. doi: 10.1038/cddis.2013.417. Erratum in: Cell Death Dis. 2017 Apr 13;8(4):e2751.

16.

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G.

Clin Cancer Res. 2013 Sep 15;19(18):5092-103. doi: 10.1158/1078-0432.CCR-12-2211. Epub 2013 Jul 17.

17.

[Influence of activator and inhibitors of Ca2+ channels on proliferative activity in Tetrahymena pyriformis infusoria].

Shemarova IV, Selivanova GV, Vlasova TD.

Ontogenez. 2012 Jul-Aug;43(4):278-86. Russian.

PMID:
23035584
18.

Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.

Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, Selivanova G.

Cell Death Differ. 2012 Dec;19(12):1992-2002. doi: 10.1038/cdd.2012.89. Epub 2012 Jul 13.

19.

Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo.

Smith SD, Enge M, Bao W, Thullberg M, Costa TD, Olofsson H, Gashi B, Selivanova G, Strömblad S.

J Biol Chem. 2012 Aug 24;287(35):29336-47. doi: 10.1074/jbc.M112.341917. Epub 2012 Jul 6.

20.

A novel facet of tumor suppression by p53: Induction of tumor immunogenicity.

Li H, Lakshmikanth T, Carbone E, Selivanova G.

Oncoimmunology. 2012 Jul 1;1(4):541-543.

21.

Up-to-date concentrations of long-lived artificial radionuclides in the Tom and Ob rivers in the area influenced by discharges from Siberian chemical combine.

Nikitin AI, Kryshev II, Bashkirov NI, Valetova NK, Dunaev GE, Kabanov AI, Katrich IY, Krutovsky AO, Nikitin VA, Petrenko GI, Polukhina AM, Selivanova GV, Shkuro VN.

J Environ Radioact. 2012 Jun;108:15-23. doi: 10.1016/j.jenvrad.2011.11.013. Epub 2011 Dec 6.

PMID:
22153591
22.

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2.

Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, Kärre K, Carbone E, Selivanova G.

Cell Cycle. 2011 Oct 1;10(19):3346-58. doi: 10.4161/cc.10.19.17630. Epub 2011 Oct 1.

PMID:
21941086
23.

Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer.

Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, Enge M, Kel A, Selivanova G.

J Biol Chem. 2011 Dec 2;286(48):41600-15. doi: 10.1074/jbc.M111.240812. Epub 2011 Aug 23.

24.

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.

Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F, Teunisse AF, Verlaan-de Vries M, Grinkevich V, Jochemsen AG, Selivanova G.

Cell Death Differ. 2011 Nov;18(11):1736-45. doi: 10.1038/cdd.2011.45. Epub 2011 May 6.

25.

PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS.

Clin Cancer Res. 2011 May 1;17(9):2830-41. doi: 10.1158/1078-0432.CCR-10-3168. Epub 2011 Mar 17.

26.

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.

Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Strömblad S.

Cell Cycle. 2011 Jan 15;10(2):301-7. Epub 2011 Jan 15.

PMID:
21239882
27.

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G.

Cell Cycle. 2010 May;9(9):1847-55. Epub 2010 May 15.

PMID:
20436301
28.

Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation.

Zhao CY, Szekely L, Bao W, Selivanova G.

Cancer Res. 2010 Apr 15;70(8):3372-81. doi: 10.1158/0008-5472.CAN-09-2787. Erratum in: Cancer Res. 2017 Jul 1;77(13):3719.

29.

Therapeutic targeting of p53 by small molecules.

Selivanova G.

Semin Cancer Biol. 2010 Feb;20(1):46-56. doi: 10.1016/j.semcancer.2010.02.006. Epub 2010 Mar 3. Review.

PMID:
20206268
30.

Integrins and mutant p53 on the road to metastasis.

Selivanova G, Ivaska J.

Cell. 2009 Dec 24;139(7):1220-2. doi: 10.1016/j.cell.2009.12.016.

31.

[Risk factors influencing the development of gastroduodenal bleeding].

Orobeĭ IuA, Lazebnik LB, Nikolaeva ÉI, Selivanova GB.

Eksp Klin Gastroenterol. 2010;(12):31-6. Russian.

PMID:
21560618
32.

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.

Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G.

Cell Cycle. 2009 Nov 1;8(21):3584-91. Epub 2009 Nov 1.

PMID:
19838062
33.

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, Soddu S.

Cancer Res. 2009 Aug 1;69(15):6241-8. doi: 10.1158/0008-5472.CAN-09-0337. Epub 2009 Jul 28.

34.

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G.

Cancer Cell. 2009 May 5;15(5):441-53. doi: 10.1016/j.ccr.2009.03.021. Erratum in: Cancer Cell. 2017 May 8;31(5):724-726.

35.

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.

Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G.

Cancer Cell. 2009 Mar 3;15(3):171-83. doi: 10.1016/j.ccr.2009.01.019. Erratum in: Cancer Cell. 2009 Jul 7;16(1):79.

36.
37.

Tumor-specific induction of apoptosis by a p53-reactivating compound.

Hedström E, Issaeva N, Enge M, Selivanova G.

Exp Cell Res. 2009 Feb 1;315(3):451-61. doi: 10.1016/j.yexcr.2008.11.009. Epub 2008 Dec 3.

PMID:
19071110
38.

The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances.

Zawacka-Pankau J, Krachulec J, Grulkowski I, Bielawski KP, Selivanova G.

Toxicol Appl Pharmacol. 2008 Nov 1;232(3):487-97. doi: 10.1016/j.taap.2008.07.012. Epub 2008 Jul 22. Review.

PMID:
18721824
39.

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C.

Br J Haematol. 2008 May;141(4):445-53. doi: 10.1111/j.1365-2141.2008.07046.x. Epub 2008 Mar 12.

PMID:
18341636
40.

[Cellular aspects of hypertrophic cardiomyopathy pathogenesis: the role of cardiomyocyte polyploidy and activation of the proliferating cell nuclear antigen in the myocardium].

Shliakhto EV, Bokeriia LA, Rybakova MG, Semernin EN, Selivanova GV, Vlasova TD, Borisov KV, Parfenov VN, Gudkova AIa.

Tsitologiia. 2007;49(10):817-23. Russian.

PMID:
18074770
41.

Kaposi's sarcoma herpesvirus load in biopsies of cutaneous and oral Kaposi's sarcoma lesions.

Pak F, Mwakigonja AR, Kokhaei P, Hosseinzadeh N, Pyakurel P, Kaaya E, Bogdanovic G, Selivanova G, Biberfeld P.

Eur J Cancer. 2007 Aug;43(12):1877-82. Epub 2007 Jul 12.

PMID:
17627810
42.

[The influence of the EGF on proliferative signal transduction in ciliate Tetrahymena pyriformis].

Shemarova IV, Selivanova GV, Vlasova TD.

Tsitologiia. 2007;49(2):156-60. Russian.

PMID:
17432601
43.

Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

Selivanova G, Wiman KG.

Oncogene. 2007 Apr 2;26(15):2243-54. Review.

PMID:
17401433
44.

Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner.

Zawacka-Pankau J, Issaeva N, Hossain S, Pramanik A, Selivanova G, Podhajska AJ.

J Biol Chem. 2007 Jan 26;282(4):2466-72. Epub 2006 Nov 29.

45.

The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.

Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, Milner J, Orlova EV.

EMBO J. 2006 Nov 1;25(21):5191-200. Epub 2006 Oct 19.

46.

Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis.

Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG.

Cell Death Differ. 2007 Mar;14(3):411-21. Epub 2006 Aug 18.

47.

HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53.

Hallgren O, Gustafsson L, Irjala H, Selivanova G, Orrenius S, Svanborg C.

Apoptosis. 2006 Feb;11(2):221-33.

PMID:
16502260
48.

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.

Nahi H, Merup M, Lehmann S, Bengtzen S, Möllgård L, Selivanova G, Wiman KG, Paul C.

Br J Haematol. 2006 Jan;132(2):230-6.

PMID:
16398657
49.

Dose-response for radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes.

Torudd J, Protopopova M, Sarimov R, Nygren J, Eriksson S, Marková E, Chovanec M, Selivanova G, Belyaev IY.

Int J Radiat Biol. 2005 Feb;81(2):125-38.

PMID:
16019922
50.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2005 Aug 26;280(34):30384-91. Epub 2005 Jul 1. Erratum in: J Biol Chem. 2017 Dec 1;292(48):19607.

Supplemental Content

Loading ...
Support Center